Given the reported involvement of the OBSCN gene in different forms of cardiomyopathies (19) along with the elevation of obscurins in preclinical models of myocardial hypertrophy and ventricular tachycardia (17, 61, 62), our findings demonstrating upregulation of the obscurin-B/phospho-N-cadherin axis in end-stage DCM may be of high pathophysiological relevance. This evidence concerns the gene OBSCN and cardiomyopathy.